anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a composite coating powder for cosmetics and a cosmetic composition including the same. The composite coating powder for cosmetics according to the present invention comprises 80-98 wt% of an inorganic powder, 0.1-10 wt% of a lipid composite, and 1.9-10 wt% of silicon oil or alkyl silane. The lipid composite, based on the total weight of the lipid composite, includes 1-5 wt% of natural ceramide, 4-15 wt% of alkanol amide, 5-10 wt% of cholesterol or a derivative thereof, 20-40 wt% of fatty acid, and 30-50 wt% of alcohol. The composite coating powder for cosmetics of the present invention uses both a silicon compound or an alkyl silane compound, which exhibits excellent water repellency and lubrication but has weak moisturizing properties, and a lipid composite, which exhibits excellent moisturizing properties by means of moisture absorption and retention through a multilayer lamella structure but has weak water repellency, exhibits cohesiveness, and is not harmonized well with other components. Accordingly, skin barriers are reinforced and improved, and soft feel of use, excellent skin protecting effects, high water repellency, and excellent dispersibility are ensured. Consequently, a cosmetic composition containing the functional composite coating powder for cosmetics can be skin-friendly and effectively applied even to skin on which a general makeup cosmetic product is difficult to use due to damaged skin barrier functions, such as sensitive skin, dry skin, and atopic dermatitis.
Patients receive cyclophosphamide to reduce B cells before CD19-CART infusion. It will also reduce the side effects of cell damage due to antitumor activity.
This group performs a 12-week individual tailored home exercise programme in accordance with the manual of Otago exercise programme. Physiotherapists visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone are performed the weeks when no visits are scheduled. Additionally, the participants receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant are provided with a walking plan and be encouraged to walk twice weekly.
The present invention provides medicinal solution which can be externally used for diminishing inflammation and relieving itch, and a finished Chinese medicinal capsule which can be internally used. The oily medicinal solution is prepared from mineral oil, olive oil and so on; the compound Chinese medicine is made by mixing the dipping extract of cortex dictamni, Chinese wingnut leaf, radix stemonae and so on in Chinese medicinal ethanol and the boiling water solution, or singly packaging and binding the Chinese medicinal herbs. The medicinal solution has the characteristics of convenient use when applied after bathing. The efficiency can reach above 90 percent. The cortex dictamni, Chinese wingnut leaf, radix stemonae, heracleum hemsleyanum michaux, and leaf or stem of persimmon are added to prepare the Chinese medicinal capsule. The Chinese medicinal capsule can be used for fundamentally treating sirocco and poison gas of lung, and skin itch, so that the itch and other skin diseases can not relapse. Simultaneously, the Chinese medicinal capsule can effectively prevent the age pigment, and has no toxic side effects but significant curative effects. The Chinese medicinal capsule is characterized by the capability of treating the skin itch including the age pigment.
The invention comprises indole derivatives of the general Formula I wherein R represents a hydrogen or halogen atom and R 1 represents 3-pyridyl or 4-pyridyl and their pharmaceutically acceptable acid addition salts with inorganic or organic acids. They are prepared by cyclizing by known methods a compound of the general formula wherein A represents hydrogen and B represents a phenylhydrazone group substituted in the 4-position according to the meaning of R above, or A represents an anilino group substituted in the 4-position according to the meaning of R and B represents oxygen, or A represents a 2-aminophenyl group substituted in the 5-position according to the meaning of R and B represents oxygen, and R 1 is as defined above, in the presence of a protonating agent, or by cyclizing by known methods a compound of the formula wherein R and R 1 are as defined above, in the presence of a protonating agent, and if desired converting the compounds of Formula I to their acid addition salts with inorganic or organic acids. 3 - Propionylpyridine 4 - chlorophenylhydrazone is prepared by reacting 4-chlorophenylhydrazine with 3-propionylpyridine. 4 - Propionylpyridine phenyl hydrazone is prepared by reacting 4 - propionylpyridine with phenyl hydrazine. 3 - [2 - (2 - amino phenyl) - propionyl] pyridine is prepared by reducing 3 - [2 - (2 - nitro phenyl) - propionyl]pyridine which is prepared by reacting 3-bromopyridine with ethyl 2-(2-nitrophenyl)- propionate and butyl-lithium. Pharmaceutical compositions comprising as active ingredients compounds of Formula I together with a pharmaceutically acceptable diluent or carrier are administered orally or parenterally and are used in the treatment of hyperaldosteronism.
Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
Chemotherapy-induced neuropathy (CIN)-pain, numbness, or tingling distributed in the hands and feet-produces persistent symptoms affecting sensation and balance in cancer survivors. Up to 50% of cancer survivors still suffer CIN 6 years after treatment. Duloxetine, the only recommended drug by the American Society of Clinical Oncology, was found to be superior to placebo but improved CIN by only 0.73 points (0-10 scale). No effective treatment for CIN has been established except exercise, with an effect size of \<0.508. Opioids relieve CIN pain, but long-term use is strongly discouraged due to opioid overuse.

The investigators propose to test auricular point acupressure (APA), an innovative and scalable solution developed from auricular acupuncture. APA is a non-invasive (needleless) and active treatment for patients with pain, whereas acupuncture is an invasive (using needles) and passive treatment (administered by a licensed practitioner). In APA, small seeds are taped on specific ear points by a skilled provider and patients press on the seeds to stimulate ear points three times daily, three minutes per time, for a total of nine minutes per day. APA provides pain relief within 1-2 minutes after ear stimulation and sustains pain relief for one month after a 4-week APA intervention. APA is popular in Taiwan, China, and Europe. Though its use is sparse in the U.S., a limited number of clinical trials have supported APA in pain management.
Participants will sleep for approximately a two hour period and receive TES SO via the NeuroConn DC Stimulator PLUS during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
OBJECTIVES: Post-acute sequelae of SARS-CoV-2 (PASC) are known for their prolonged and persistent effects on patients. This study aimed to investigate the impact of the PASC on the quality of life (QOL) of patients, their levels of activity participation, and satisfaction with these levels, in addition to exploring whether the duration of post-intensive care unit (ICU) discharge is associated with the effects of PASC.
SUBJECT AND METHODS: This cross-sectional study included 134 patients with COVID-19 discharged from an ICU in Kuwait. Data were collected using two validated questionnaires: the World Health Organization Quality of Life-Brief (WHOQOL-BREF) and Satisfaction with Daily Occupations. Additionally, demographic information was collected, and 11 categories of related symptoms were investigated.
RESULTS: Most patients reported health issues post-ICU discharge. Furthermore, most PASC-related symptoms decreased over time, whereas a few increased. Notably, we observed a negative association between post-discharge duration and overall improvement in level of participation in activities of daily living. However, patients discharged from the ICU for more than 6 months demonstrated higher satisfaction with functional performance and improved QOL. Additionally, patients who received rehabilitation, and were vaccinated were less likely to have poor QOL. No significant sex differences were observed in the WHOQOL-BREF score.
CONCLUSION: PASC adversely affected the daily functioning of patients, especially in leisure, social, and religious aspects. However, these effects lessened over time, with corresponding improvement in QOL. Additionally, patient satisfaction with functional performance increased over time. These findings shed light on the rehabilitation needs of patients with COVID-19.
The subjects of this study are patients with non-load-bearing bone defects of the extremities who need bone grafting surgery. The subjects were randomly divided into experimental group and control group. The experimental group was treated with bone graft using magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd., while the control group was treated with bone graft β- Tricalcium phosphate bioceramics were used for bone transplantation. Three follow-up visits were performed at the 12th, 24th and 36th weeks after bone grafting. It is estimated that 176 cases will be recruited in total, and 135 cases have been recruited since April 2021. This product can be degraded and absorbed in vivo, and it can promote the formation of new bone.
Nasal swabs will be tested by nursing personnel at each intervention site using SOFIA Fluorescent Immunoassay Analyzer Influenza A+B (LTCF with RIDT). Anonymous results will be sent, via wireless transmission, for daily review by the study team and public health personnel. A positive influenza detection will trigger direct communication with LTCF personnel with advice on antiviral treatment, antiviral prophylaxis, and appropriate infection control practices. We will collect data from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns.
Group-based parent psychoeducation will be provided to the control group. This program will also be delivered in a telehealth format across 10 sessions (1 1-hour session per week for 10 weeks) and will cover a broad range of information relevant to ASD.
Eligible children will be enrolled, randomized, and followed at six-month intervals for two years with all children wearing single vision lenses for the second year. At each visit, complete measurements of the components of the eye will be made to explain the mechanism responsible for the Progressive Addition Lens (PAL) treatment effect and why it occurs mainly during the first year of bifocal wear (Gwiazda et al. 2003). While hyperopic retinal blur (blur at the back of the eye) due to accommodative lag (poor focusing when doing close work) has been proposed as a possible mechanism driving myopia progression (Gwiazda et al. 1993), others have shown that accommodative lag accompanies rather than precedes the onset of myopia (Mutti et al., 2006). This suggests that accommodative lag is a result of another possible mechanism resulting in myopia progression such as crystalline lens-induced ciliary-choroidal tension (a model in which the lens in the eye is stretched and is not as good at focusing up close) (Mutti et al., 2000). According to this proposed mechanism, high accommodative lag in myopia results from increased crystalline lens tension that is transmitted through the choroid (an outside layer of the eye). This tension results in restricted equatorial (the vertical dimension of the eye) eye growth with no axial (front to back) restriction to eye growth and yields a prolate ocular shape (an eye that is longer than it is wide) in myopes (Mutti et al., 2000).

Comparisons: Refractive error (glasses prescription), axial length (length of the eye), peripheral eye shape, accommodation (focusing ability), corneal shape (shape of the front of the eye), anterior chamber depth, crystalline lens thickness and curvatures (shape of the lens in the eye), central and peripheral higher-order aberrations (how well light focuses in the eye), and phoria (eye alignment) will be measured at six-month intervals. The primary study outcome is refractive error measured by cycloplegic autorefraction. Comparison of the biometric data collected both during the first year when the PAL intervention is present and during the second year when the PAL intervention is removed will allow us to differentiate between the two theories under consideration. We will also evaluate whether the modest PAL treatment effect that has been reported during the first year of PAL wear is permanent.
PURPOSE:To obtain the title material causing little color change by polymerization and having excellent beautifulness and mechanical strength, by using a polymerizable monomer, a polymerization initiator and a powder filler as main components, wherein the filler exceeding a specific average particle diameter is composed of two or more components having a specific refractive index. CONSTITUTION:The objective material contains a polymerizable monomer [preferably (meth)acrylic acid esters or urethane (meth)acrylates], a polymerization initiator (e.g. a peroxide and a promoter) and a powdery filling material (e.g. glass powder) as main components, wherein said filling material is composed of the component having an average particle diameter of >=0.1mum as a filler and the other components as a matrix and contains at least one kind of filler satisfying the relationship of formula I and a filler satisfying the formula II. In the formulas, nm and np are refractive indices of the matrix before polymerization and after polymerization, respectively and nf is refractive index of the filler. The compounding ratio of the fillers having different refractive indices is preferably 15-85wt.% to 85-15wt.%.
Dentures of artificial resin are provided with a soft lining by applying thereto a soft, resilient plastic plate or foil, which has been swollen in a monomeric, polymerizable vinyl compound, and polymerizing the swollen compounds by heat and pressure in the presence of a catalyst.  The plates or foils may be copolymers derived from vinyl components which normally yield hard plastics, e.g. methyl methacrylate and at least one other vinyl component which yields soft plastics, e.g. ethyl acrylate, butyl acrylate, hexyl acrylate, octyl acrylate, isobutyl methacrylate, isohexyl methacrylate, octyl methacrylate and n-lauryl methacrylate.  It is advantageous to use foils prepared from cross-linked copolymers such as are obtained by complementary use of polyfunctional vinyl compounds, e.g. divinyl benzene, glycol diacrylate, glycol dimethacrylate, butanediol dimethacrylate and hexanediol dimethacrylate.  The swelling compound is preferably the same monomer or mixture as that used for making the resilient foil but others may be used, examples being methyl methacrylate, ethyl methacrylate, butyl methacrylate, isohexyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate and octyl acrylate. Particularly good adhesion with a polymethyl methacrylate denture is obtained by swelling with methyl methacrylate, butyl methacrylate, isobutyl methacrylate, isohexyl methacrylate and mixtures of methyl methacrylate and acrylates containing more than 50 per cent. methyl methacrylate.  Polymerization catalysts may be dissolved in the swelling compound or a second foil, superficially impregnated with the catalyst, may be placed over the plate or foil to be swollen. Suitable catalysts include benzoyl peroxide, p-chlorobenzoyl peroxide and cumene hydroperoxide.  Known redox systems, such as those using trihexyl amine or p-toluene sulphinic acid are also suitable, and in this case it is advantageous to incorporate the oxidation agent in the plate and the reducing agent in the swelling monomer.ALSO:Dentures of artificial resin are provided with a soft lining by applying thereto a soft, resilient plastic plate, which has been swelled in a monomeric polymerizable vinyl compound, and polymerizing the swelled compounds by applying heat and pressure in the presence of a catalyst.  Various examples of suitable materials are given (see Group IV(a)).
There is no experience with overdose of MAVENCLAD. Lymphopenia is known to be dose- dependent. Particularly close monitoring of hematological parameters is recommended in patients who have been exposed to an overdose of MAVENCLAD [see Warnings and Precautions (5.3, 5.5)].

There is no known specific antidote to an overdose of MAVENCLAD. Treatment consists of careful observation and initiation of appropriate supportive measures. Discontinuation of MAVENCLAD may need to be considered. Because of the rapid and extensive intracellular and tissue distribution, hemodialysis is unlikely to eliminate cladribine to a significant extent.
FIELD: molecular biology. SUBSTANCE: invention describes graphite nanotubes that comprise tubular fullerenes and fibrils that are functionalized by chemical substitution or adsorption of functional moieties of biological molecules. Invention relates to graphite nanotubes that are substituted with molecule chemical moieties uniformly or non-uniformly or containing some cyclic compounds adsorbed on nanotubes and to complex structures consisting of such functionalized nanotubes linked with each other. Invention relates also to methods of incorporation of functional groups on surface of such nanotubes. EFFECT: expanded arsenal of biologically active agents. 63 cl, 10 dwg, 5 ex
INTRODUCTION: Correct diagnosis of acute appendicitis may sometimes be challenging. The Negative appendectomy rate (NAR) has declined in the recent years in Europe and USA, in part due to better diagnostic imaging tools. The aim of this study was to examine the rates of negative appendectomy in our institution, investigate trends in its incidence, and identify possible predicting factors.
METHODS: A retrospective cohort study, including all patients younger than 18 years of age who underwent an appendectomy between 2007 and 2021 in a single tertiary medical center. Data regarding patient's demographics, laboratory and imaging results, pathological results and clinical outcome were collected.
RESULTS: Between 2007 and 2021, a total of 3937 pediatric patients underwent appendectomy due to a working diagnosis of acute appendicitis. Overall, 143 patients (3.6%) had normal appendix on pathological examination. However, in the last 5 years, the rate of normal appendix was 1.9%, together with an increased rate of pre-operative imaging (from 40% to nearly 100%).
CONCLUSION: Low NAR under 2% is an achievable benchmark in the era of accessible pre-operative imaging. In unequivocal cases, a secondary survey that includes repeated physical examination, blood work and imaging is recommended and may result in near-zero rates of NAR.
An information pamphlet for patients is included with the product. Patients and their caregivers should be aware of the following information:

1\. Reversibility of the suppressive effects of nafarelin has been demonstrated by the appearance or return of menses, by the return of pubertal gonadotropin and gonadal sex steroid levels, and/or by advancement of secondary sexual development. Semen analysis was normal in the two ejaculated specimens obtained thus far from boys who have been taken off therapy to resume puberty. Fertility has not been documented by pregnancies and the effect of long-term use of the drug on fertility is not known.

2\. Patients and their caregivers should be adequately counseled to assure full compliance; irregular or incomplete daily doses may result in stimulation of the pituitary-gonadal axis.

3\. Inform parents and caregivers that reports of convulsions have been observed in patients receiving GnRH agonists. Patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions may be at increased risk [see Warnings].

4\. Inform patients and caregivers that reports of pseudotumor cerebri (idiopathic intracranial hypertension) have been observed in pediatric patients receiving GnRH agonists. Advise patients and caregivers to monitor for headache, and vision issues such as blurred vision, double vision, loss of vision, pain behind the eye or pain with eye movement, ringing in the ears, dizziness, and nausea. Advise patients and caregivers to contact their healthcare provider if the patient develops any of these symptoms [see Warnings].

5\. During the first month of treatment with SYNAREL, some signs of puberty, e.g., vaginal bleeding or breast enlargement, may occur. This is the expected initial effect of the drug. Such changes should resolve soon after the first month. If such resolution does not occur within the first two months of treatment, this may be due to lack of compliance or the presence of gonadotropin independent sexual precocity. If both possibilities are definitively excluded, the dose of SYNAREL may be increased to 1800 µg/day administered as 600 µg tid.

6\. Patients with intercurrent rhinitis should consult their physician for the use of a topical nasal decongestant. If the use of a topical nasal decongestant is required during treatment with SYNAREL, the decongestant should not be used until at least 2 hours following dosing with SYNAREL.

Sneezing during or immediately after dosing with SYNAREL should be avoided, if possible, since this may impair drug absorption.
Participants will consume three daily placebo drinks (one before each meal) for 2 weeks. .
Inflammatory arthritis leads to peripheral nerve sensitization, but the therapeutic effect is often unsatisfactory. Our preliminary studies have found that in mice with inflammatory arthritis, the use of ionotropic glutamate receptor antagonists can produce a good analgesic effect without altering foot swelling, suggesting that pain relief may be related to the improvement of neuropathic pain. However, the underlying mechanisms remain unclear. To further investigate the effects of neuropathic pain medications on inflammatory arthritis and the impact of the ionotropic glutamate receptor NR2B subunit (NR2B) on inflammatory arthritis, this study employed gabapentin (GBP) treatment on the inflammatory arthritis mouse model (the adjuvant induced arthritis, AIA), and we found a significant reduction in pain. Further studies revealed that in AIA, the expression levels of NR2B, TRPV1, pain-related molecules (substance P, PGE2), inflammatory cytokines (IL-1, IL-6, TNF-α, and GM-CSF) and Ca2+ were elevated in the foot and dorsal root ganglia (DRG). GBP treatment was able to influence the downregulation of the expression levels of NR2B, TRPV1, pain-related molecules, inflammatory cytokines and Ca2+. Mechanistic studies have shown that GBP treatment affects the downregulation of NR2B, and the downregulation of NR2B expression leads to the downregulation of TRPV1, pain-related molecules and inflammatory cytokines, thereby alleviating pain. These results suggest that in peripheral sensitization caused by AIA, GBP can play a role in improving pain, and NR2B may be a key target of peripheral nerve sensitization induced by inflammatory arthritis. GBP provides a theoretical basis for the clinical treatment of inflammatory arthritis.